Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02341482 · ClinicalTrials.gov registry record · Phase 1

A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of PF-04958242 in Healthy Subjects

A Phase 1 study, sponsored by Biogen.

Completed
Registry status
Phase 1
Development phase
13
Enrollment target

NCT02341482: Completed Phase 1 study, sponsored by Biogen.

NCT02341482 is a Phase 1 study that has completed, run by Biogen. The registered enrollment target is 13 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (78% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02341482, a Phase 1 study, has completed, sponsored by Biogen.

COMPLETED
Registry status
Phase 1
Development phase
13 participants
Enrollment target

Study Summary

The purpose of the current study is to characterize the pharmacokinetic (PK) profile of PF 04958242 when co administered with a strong cytochrome P450 3A4 (CYP3A4) inhibitor.

Primary Outcome

AUCtau = area under the concentration-time profile from time 0 to time tau, the dosing interval, where tau = 12 hours. Collected at Day 3 for PF-04958242 0.025 mg Arm and Day 17 for PF-04958242 0.025 mg + itraconazole 200 mg Arm.

Interventions

  • DRUG Itraconazole
  • DRUG PF-04958242

Trial Details

FieldValue
Enrollment Target 13 participants
Start Date 2015-02-05
Est. Completion 2015-03-31
Phase Phase 1
Biogen

334 total trials

What the finished NCT02341482 record still lists

NCT02341482 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (78% lower).

The record links to 0 conditions, and to 2 interventions - of which Itraconazole is the first listed.

NCT02341482 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02341482 about?

NCT02341482 is a clinical study titled "A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of PF-04958242 in Healthy Subjects". The purpose of the current study is to characterize the pharmacokinetic (PK) profile of PF 04958242 when co administered with a strong cytochrome P450 3A4 (CYP3A4) inhibitor.

What is the current status of trial NCT02341482?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2015-02-05. Estimated completion is 2015-03-31.

What interventions are being tested in trial NCT02341482?

The interventions under investigation include: Itraconazole (DRUG), PF-04958242 (DRUG).

Who is sponsoring clinical trial NCT02341482?

This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02341482's enrollment target sits among peer trials

13 1847th of 2000 higher than 149 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03125655 · 13 participants

    Regulation of Inflammatory Genes in Psoriasis

  • NCT03774446 · 13 participants · Phase 2

    Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease

  • NCT03830151 · 13 participants · Phase 1

    Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors

  • NCT04573231 · 13 participants · Phase 2

    Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02341482, the US trial registry maintained by the National Library of Medicine. NCT02341482 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.